Kabutaro's purchase
Purchase date: 2025-11-19
Amount: JPY 100,000
Quantity: 10 shares
Price per share: JPY 10,000
Type: Common stock
Angel tax scheme: Eligible (Type A)
Basic information
Company: Orchard Bio Inc.
Field: Regenerative medicine (cell-based drugs)
Listing status: Unlisted (aims for an IPO)
Links
FUNDINNO project page (Japanese)
This page is a translation of the Japanese page, which is updated first: Japanese version
Company profile
Founded: March 2021
Head office: Kobe, Hyogo
Representative: Tetsuo Uematsu, CEO
Capital: JPY 63,800,000 (as of October 8, 2025)
Sales: JPY 0 (2024), about JPY 19 million (2026 plan)
Offering terms
Target amount: JPY 6,000,000
Maximum amount: JPY 50,000,000
Shareholder benefits
None
Business
Orchard Bio develops hAP cells: drugs that drug makers gave up on because they were too toxic are loaded into cells and delivered in small amounts only to the diseased area. This was its second fundraising on FUNDINNO, after 2023.
・hAP cells: Combine cells and drugs to reduce toxicity
・Homing effect: The cells gather at the lesion by themselves, reducing side effects
・Plan: Develops several candidates in parallel and also offers regulatory consulting for regenerative medicine
Notes
FUNDINNO investments are unlisted shares, so they cannot be sold until the company lists or is acquired. Company details and plans are based on the FUNDINNO project page and the company's announcements.
Current status
Listing / M&A: –
Valuation: –
Related pages: IPO / Trade History / Annual Results